Document:

This GBI - 2003(C) Stock Award Plans (the "Plan") is made as of the
18th day of August 2003 by Genesis Bioventures, Inc. (the "Company") for the
Company's securities attorney, Richard S. Lane,("the Recipient").

RECITALS:

           The Company desires under agreement to grant to Recipient in exchange
for services provided by Recipient to the Company, shares of the common stock of
the Company ( "Common Stock"), pursuant to the provisions set forth herein;

           1. Grant of Shares. The Company shall grant to the Recipient 50,000
shares of Common Stock (the "Shares").

           2. Services. Recipient has provide bona fide services to the Company
not in connection with capital raising activities.

           3. Compensation. Recipient's compensation is the Shares identified
herein. The parties agree the Shares are valued at $.0 1 each. Recipient is
responsible for all income taxes.

           4. Registration. Notwithstanding anything to the contrary contained
herein, the Shares will be registered on Form S-8 Registration Statement dated
no later than the month of August 2003.

           5. Delivery of Shares. The Company shall deliver the Shares to the
Recipient.

           6. Waiver. No waiver is enforceable unless in writing and signed by
the waiving party and any waiver shall not be construed as a waiver of any other
or subsequent breach.

           7. Amendments. This Plan may not be amended unless by the mutual
consent of all of the parties hereto in writing.

           8. Governing Law. This Plan shall be governed by the laws of the
State of New York, and the sole venue for any action arising hereunder shall be
any Federal or State Court located in New York City, New York.

           9. Assignment and Binding Effect. Neither this Plan nor any of the
rights, interests or obligations hereunder shall be assigned by any party hereto
without the prior written consent of the

<PAGE>

other parties hereto, except as otherwise provided herein. This Plan shall be
binding upon and for the benefit of the parties hereto and their respective
heirs and permitted assignees.

           10. Integration and Captions. This Plan includes the entire
understanding of the parties hereto with respect to the subject matter hereof.
The captions herein are for convenience and shall not control the interpretation
of this Plan.

           11. Legal Representation. No tax advice has been provided to any
party by any other party and the Recipient is cautioned to retain its own
qualified tax advisor with respect to any tax consequences that may impact upon
him individually.

           12. Construction. Each party acknowledges having had the opportunity
to review, negotiate and approve all of the provisions of this Plan.

           13. Cooperation. The parties agree to execute such reasonable
necessary documents upon advice of legal counsel in order to carry out the
intent and purpose of this Plan as set forth herein .

           14. Hand-Written provisions. Any hand-written provisions hereon, if
any, or attached hereto, which have been initialed by all of the parties hereto,
shall control all typewritten provisions in conflict therewith.

           15. Fees, Costs and Expenses. Each of the parties hereto acknowledges
and agrees to pay, without reimbursement from the other party , the fees, costs,
and expenses incurred by each such party incident to this Plan.

           16. Consents and Authorizations. By the execution herein below, each
party (i) acknowledges and agrees that each such party has the full right,
power, legal capacity and authority to enter into this Plan, and the same
constitutes a valid and legally binding Plan in accordance with the terms,
conditions and other provisions contained herein; and (ii) acknowledges the
receipt of an executed copy hereof.

           17. Gender and Number. Unless the context otherwise requires,
references in this Plan in any gender shall be construed to include all other
genders, references in the singular shall be construed to include the plural,
and references in the plural shall be construed to include the singular.

                                        2

<PAGE>

           18. Severability. In the event anyone or more of the provisions of
this Plan shall be deemed unenforceable by any court of competent jurisdiction
for any reason whatsoever, this Plan shall be construed as if such unenforceable
provision had never been contained herein.

GENESIS BIOVENTURES, INC.

By____________________________                         Date: August 18, 2003
E. Greg McCartney, President

RECIPIENT

Signature _______________________

Print Name     RICHARD S. LANE                         Date: August 18, 2003
           -------------------------------

                                        3

<PAGE>Cross License Agreement

	

EXECUTION COPY  

CROSS LICENSE
AGREEMENT  

AGREEMENT, dated as of this 31st day
of August, 2000, (“Effective Date”) by and between IMS Health Incorporated
(hereinafter “IMS”), a Delaware corporation with an address at 200 Nyala Farms,
Westport, Connecticut 06880, for and on behalf of the Affiliates listed in the Exhibits
hereto, and Synavant Inc. (hereinafter “ST”), a Delaware corporation, with an
address at 3445 Peachtree Road, N.E., Suite 1400, Atlanta, Georgia 30326 for and on behalf
of the Affiliates listed in the Exhibits hereto. 

RECITALS  

WHEREAS, IMS, among other things,
provides information services to the pharmaceutical industry; 

WHEREAS, ST , among other things, collects
and makes commercially available certain demographic and profiling information on health
care professionals (e.g., doctors, nurses, pharmacists) and health care providers (e.g.,
hospitals, pharmacies, clinics) in various countries around the world (“Pharbase
Services”); and 

WHEREAS, IMS desires to provide
certain health care data to ST for use in connection with it’s Pharbase(TM) Services,
and ST desires to provide information from it’s Pharbase Services to IMS for use in
it’s information services, all in accordance with and subject to the terms set forth
in this Agreement; 

NOW, THEREFORE, in consideration of
the foregoing and of the mutual promises herein contained, the parties agree as follows: 

ARTICLE I —DEFINITIONS  

For purposes of this Agreement, the
following terms shall have the meanings specified: 

1.1     “Affiliate” means
any Entity which now or in the future controls, is controlled by or is under common
control with a party hereto.  

1.2     “Contract
Year” means each 12-month period commencing on September 1st and ending on August
30th during the term of this Agreement.  

1.3     “Desktop
Media” means prescription pads, medical forms and other similar promotional material
which are provided to Prescribers at a nominal charge or without charge, and which
contain advertising relating to one or more Legended Drugs.  

	

1.4     “Entity” means
any corporation, business trust, joint venture, association, company, firm, partnership,
government entity or other entity.  

1.5     “Healthcare
Company” means (i) a manufacturer of Legended Drugs or any Person licensed by such a
manufacturer to market and sell Legended Drugs (“Manufacturer”) or an Agency;
provided, however, that neither a wholesaler of Legended Drugs, a pharmacy, nor a Person
providing mail service prescription drug programs shall be deemed a “Manufacturer”;
(ii) a manufacturer of medical supplies and/or diagnostic equipment, or any person
licensed by such a manufacturer to market and sell medical supplies and/or diagnostic
equipment; (iii) a publisher of single or multi-sponsored journals which are devoted to
medicine, health care or veterinary subjects (“Journals”); (iv) a publisher of
Desktop Media, or (v) a sponsor of continuing medical education (“CME”)
seminars, conferences or courses or a publisher of CME materials.  

1.6     “IMS
Data” means certain data from IMS as further described in exhibits attached hereto.
Each exhibit forms a part of this Agreement. Terms and conditions in said exhibit(s)
shall supersede any conflicting terms and conditions in this Agreement for only the
specific IMS Data defined in said exhibit(s).  

1.7     “Legended
Drugs” means drugs which under Federal, provincial, state or national law require
the written prescription of a doctor, osteopath or other individual who has the authority
to prescribe Legended Drugs.  

1.8     “Materials” means
(i) information, including promotional materials and solicitation materials sent to a
Prescriber, all of which relate to one or more Legended Drugs of a Manufacturer or relate
to medical supplies and/or diagnostic equipment marketed by a Healthcare Company, (ii)
surveys or questionnaires sent to a Prescriber which either seek information relating to
the prescribing or practice profile of such Prescriber or the use by such Prescriber of
medical supplies or diagnostic equipment; provided, however, that the use of such surveys
or questionnaire shall be subject to the terms of Paragraph 7(e) hereof, (iii) Journals,
(iv) Desktop Media, or (v) information, including promotional materials, solicitation
materials or course materials, relating to CME.  

1.9     “Pharbase
Data” means certain data from ST as more fully described in exhibits attached
hereto. Each exhibit forms a part of this Agreement. Terms and conditions in said
exhibit(s) shall supersede any conflicting terms and conditions in this Agreement for
only the specific Pharbase Data defined in said exhibit(s). In addition, Pharbase Data
shall include all other demographic and profiling information on health care
professionals (e.g., doctors, nurses, pharmacists) and health care providers (e.g.,
hospitals, pharmacies, clinics) then in the possession or control of ST, or any ST
Affiliate, in any country. As any new Pharbase Data or new fields of data for existing
Pharbase Data (collectively “New Data”) comes into the possession or control of
ST, or any ST Affiliate, ST shall notify IMS of such New Data within five (5) days
following its availability to ST or the applicable ST Affiliate, as the case may be, and
the Pharbase Data shall include all such New Data, without any change in fees, unless
otherwise notified by IMS to ST or to the applicable ST Affiliate.  

	

1.10     “Prescriber” means
a doctor, osteopath, dentist or other individual with an address in the country
identified in the applicable exhibits who has the authority to prescribe Legended Drugs.  

ARTICLE II - LICENSE
TO IMS DATA 

2.1     LICENSE
     GRANT
a.        IMS       hereby
grants to ST a  non-transferable  and non-exclusive  license to IMS Data for use
solely in  accordance  with the terms of Paragraph 2.3 hereof and subject to the
other terms and conditions of this Agreement.  The license granted herein is not
exclusive  and nothing  contained in this Article II shall  prohibit or restrict
IMS from  licensing,  selling or  otherwise  transferring  IMS Data or any other
information  to any other  person or Entity or from  using IMS Data or any other
information for its own purposes. 

b.                  Notwithstanding
     the terms of Paragraph  2.1(a) above,  the granting and  acceptance of each
IMS Data  license may be by IMS and ST, or an  Affiliate  of either of them,  as
specified in the applicable exhibit. 

2.2     IMS DATA

     IMS shall  provide the IMS Data to ST in  accordance  with the  operational
procedures  set  forth  in the  applicable  exhibit  hereto.  IMS  will  use its
reasonable  efforts to process IMS Data in an accurate and complete manner.  IMS
will promptly  notify  Licensee of any material  inaccuracies in such Data which
become known to IMS in  accordance  with  IMS’s  then  applicable  internal
procedures for data quality assurance. 

2.3     USE OF
IMS DATA
Subject to the other terms and conditions of this Agreement, the IMS Data
licensed hereunder shall be used by ST solely to update it’s Pharbase database(s)
identified in the applicable schedule (the “Authorized Pharbase Databases”);
provided, however, any such updated Pharbase database may only be used for the following
purposes:  

a.                  to
     select,  on behalf of a Healthcare  Company,  a list of Prescribers for the
purpose  of  sending  Materials,  developed  by or on behalf of such  Healthcare
Company, to certain of such Prescribers; 

b.                  in
     connection with ST’s drug sampling services,  to select, on behalf of
one or more Manufacturers,  a list of Prescribers,  which list ST may use solely
for the  purpose  of  sending  its order  form to  certain  of such  Prescribers
soliciting  a request  from each of such  Prescribers  for a small  quantity  of
Legended Drugs of each of such Manufacturers (a “Form”); 

c.                  to
     select,  on behalf of a publisher  of  Journals  or a publisher  of Desktop
Media, a list of Prescribers  for the purpose of determining  advertisements  to
appear in a Journal or in Desktop Media; 

d.                  to
     select, on behalf of a Manufacturer,  a list of Prescribers for the purpose
of  sending  Legended  Drug  samples  of such  Manufacturer  to  certain of such
Prescribers; or 

	

e.                  for
     loading into the sales force automation  systems of a Manufacturer who is a
customer of ST for such systems for use in connection with electronic  territory
management by or on behalf of such Manufacturer. 

2.4.     CONDITIONS
     APPLICABLE           TO          USE          OF          IMS          DATA

a.          Except as expressly provided
in  Paragraph  2.3,  ST shall  retain the IMS Data and any  information  derived
therefrom only within the internal confines of ST’s own  organization.  ST
shall not provide any IMS Data to any third party,  including but not limited to
a Healthcare  Company or any  affiliate  of ST,  except as  commingled  with the
Pharbase Data. 

b.                  Notwithstanding
     anything to the contrary contained herein, under no circumstances shall any
IMS Data or any information derived therefrom be provided by ST to any person or
Entity which has one or more lines of business engaged in the licensing, selling
or providing of access to data, information or databases in competition with IMS
or any  Affiliate  (“Competing  Company”),  or any  person  or  Entity
controlling,  controlled  by or under common  control with a Competing  Company,
including  but not  limited  to the  Competing  Companies  listed on  Exhibit 3;
provided,  however,  that nothing  herein  shall  preclude a  Manufacturer  from
engaging  the  services of a third  party  (including  a  Competing  Company) to
provide  services  which  require  access to the Pharbase Data and in connection
therewith, ST authorizes access to Pharbase Data. 

2.5.                  PROHIBITED
     USES OF IMS DATA
IMS does not grant, and ST does not receive,  any title or
other interest in the IMS Data or any information  derived therefrom,  including
but not limited to the Limited Data, except for those rights granted  explicitly
in this Agreement;  all rights not expressly  granted to ST are reserved to IMS.
Without limiting the generality of the foregoing,  under no circumstances  shall
ST use,  possess,  distribute,  or permit any other person or Entity to use, IMS
Data  received  by ST in  connection  with this  Agreement,  or any  information
derived therefrom,  including but not limited to the Limited Data, in any manner
which: 

a.                  is
     contrary  to the terms of this  Agreement  or is  otherwise  not  expressly
permitted by the terms of this Agreement; 

b.                  will
     violate any law or regulation by such use; 

c.                  will
     violate the contractual  restrictions of any third party  identified by IMS
pursuant to Paragraph  4.1  governing  the use of such third  party’s  data
incorporated  within  the IMS Data in  effect at the time of the use of such IMS
Data, unless an authorized representative of IMS provides ST with written notice
that  such IMS Data is no  longer  subject  to the  restrictions  of such  third
party’s agreement; 

d.                  results
     in any  analysis of the IMS Data,  or any  information  derived  therefrom,
which  analysis  (i)  results  in the  disclosure  to a person  or Entity of any
information  regarding the  mathematical  algorithms,  formulas,  processes,  or
statistical  methods used by IMS to produce any of the IMS Data, (ii) is used or
made  available  for  use to  promote  or aid in the  promoting  of any  data or
information  which is not derived  from the IMS Data  (other  than the  Pharbase
Data),  or (iii)  seeks to  demonstrate  that the IMS Data,  or any  information
derived  therefrom,  is  inferior  to any  other  data,  attempts  to  show  any
deficiency  in such IMS  Data or  information,  or  otherwise  makes  statements
detrimental to IMS or any of it’s  Affiliates  concerning  such IMS Data or
information; 

	

e.                  results
     in the reverse  engineering  or  disassembling  of any of the IMS Data;  or

f.                  enhances,
     benchmarks, validates, compares with, authenticates, verifies, supplements,
or  modifies  any IMS Data  except  as  expressly  provided  in this  Agreement.

ARTICLE III —LICENSE
TO PHARBASE DATA  

3.1            LICENSE
GRANT
a.          ST hereby grants to IMS a
non-transferable and non-exclusive license to Pharbase Data for use solely in  accordance
 with the terms of Paragraph  3.3 hereof and subject to the other terms and  conditions
of this  Agreement.  The licenses  granted  herein are not exclusive and nothing
 contained in this Article III shall  prohibit or restrict ST from licensing,  selling or
otherwise transferring Pharbase Data or any other information  to any  other  Person  or
from  using  Pharbase  Data or any  other information for its own purposes.  

b.                  Notwithstanding
     the terms of Paragraph  3.1(a) above,  the granting and  acceptance of each
Pharbase  Data  license may be by IMS and ST, or an Affiliate of either of them,
as specified in the applicable exhibit. 

3.2     PHARBASE
     DATA ST shall  provide  the  Pharbase  Data to IMS in  accordance  with the
operational  procedures set forth in the applicable  exhibit hereto. ST will use
its  reasonable  efforts to process  Pharbase  Data in an accurate  and complete
manner.  ST  will  promptly  notify  IMS of any  material  inaccuracies  in such
Pharbase  Data which  become  known to ST in  accordance  with ST’s  then
applicable internal procedures for data quality assurance. 

3.3     USE OF
     PHARBASE DATA
 Subject to the other terms and conditions of this  Agreement,
the  Pharbase  Data  licensed  hereunder  shall  be used by IMS  solely  for the
following purposes:  (a) to update its prescriber  databases;  (b) to update its
sales, prescription and market research databases used principally in connection
with the delivery of sales management  information  services and market research
services  (collectively  the  updated  data  described  in (a) and (b) is hereby
referred to as the “Updated Databases”),  and (c) to create derivative
works and license  the  Updated  Databases  and such  derivative  works to third
parties in  connection  with the delivery of one or more of the services of IMS.

3.4.                  CONDITIONS
     APPLICABLE         TO        USE        OF        PHARBASE         DATA

a.          Except as expressly provided
in Paragraph 3.3, IMS shall retain the Pharbase Data and any information derived
therefrom only within the internal confines of IMS’s own organization. IMS
shall not  provide  any  Pharbase  Data to any third  party,  including  but not
limited to a Healthcare  Company or any  affiliate of ST,  except as  commingled
with IMS information or services. 

b.                  Notwithstanding
     anything to the contrary contained herein, under no circumstances shall any
uncommingled  Pharbase Data be provided by IMS to any person or Entity which has
one or more  lines of  business  engaged  in:  (i) sales  force  automation  and
customer relationship  management systems, (ii) implementation,  integration and
consulting  services relating to the foregoing,  (iii) direct marketing services
(including  direct  mail and  interactive  telephone  marketing),  and (iv) drug
sample   accountability   and  distribution,   in  each  case  relating  to  the
pharmaceutical, biotechnology, diagnostics, medical / surgical supply and health
care  industries,  in  competition  with  ST or any  Affiliate  (“Competing
Company”),or  any  person or  Entity  controlling,  controlled  by or under
common  control  with a  Competing  Company,  including  but not  limited to the
Competing Companies listed on Exhibit 4; provided,  however, that nothing herein
shall  preclude a  Manufacturer  from  engaging  the  services  of a third party
(including a Competing  Company) to provide services which require access to the
Pharbase Data and in connection  therewith,  IMS  authorizes  access to Pharbase
Data. 

	

3.5.                  PROHIBITED
     USES OF  PHARBASE  DATA ST does not grant,  and IMS does not  receive,  any
title  or  other  interest  in the  Pharbase  Data  or any  information  derived
therefrom,  except for those rights granted  explicitly in this  Agreement;  all
rights not  expressly  granted to IMS are reserved to ST.  Without  limiting the
generality of the foregoing, under no circumstances shall IMS use, or permit any
other person or Entity to use,  Pharbase Data received by IMS in connection with
this  Agreement,  or any  information  derived  therefrom,  in any manner which:

a.                  is
     contrary  to the terms of this  Agreement  or is  otherwise  not  expressly
permitted by the terms of this Agreement; 

b.                  will
     violate any law or regulation by such use; 

c.                  will
     violate the contractual  restrictions  of any third party  identified by ST
pursuant to Paragraph  4.1  governing  the use of such third  party’s  data
incorporated  within the Pharbase  Data in effect at the time of the use of such
Pharbase  Data,  unless an  authorized  representative  of ST provides  IMS with
written notice that such Pharbase Data is no longer subject to the  restrictions
of such third party’s agreement; 

d.                  results
     in any analysis of the Pharbase Data, or any information derived therefrom,
which  analysis  (i)  results in the  disclosure  to one or more  Persons of any
information  regarding the  mathematical  algorithms,  formulas,  processes,  or
statistical methods used by ST to produce any of the Pharbase Data, (ii) is used
or made  available  for use to  promote or aid in the  promoting  of any data or
information  which is not  derived  from the  Pharbase  Data,  or (iii) seeks to
demonstrate  that the Pharbase Data, or any information  derived  therefrom,  is
inferior to any other data,  attempts to show any  deficiency  in such  Pharbase
Data or information,  or otherwise makes statements detrimental to ST concerning
such Pharbase Data or information; 

e.                  results
     in the reverse engineering or disassembling of any of the Pharbase Data; or

f.                  enhances,
     benchmarks, validates, compares with, authenticates, verifies, supplements,
or modifies  any data,  products or services of IMS or any other party except as
expressly provided in this Agreement. 

	

ARTICLE IV —RESTRICTED
DATA  

4.1     Either
party may identify to the other party in writing certain elements of some or all of the
Data which incorporates information licensed to a party of this Agreement by a third
party, and which Data is subject to restrictions greater or different from the
restrictions set forth in this Agreement (“Restricted Data”). In addition to
the terms and conditions of this Agreement, the licensee hereunder agrees to treat each
element of Restricted Data in accordance with the terms required by the third party. To
the extent that any term of such a third party agreement then in effect is more
restrictive concerning the use or disclosure of Restricted Data than the terms contained
in this Agreement concerning the use or disclosure of Data, then the terms of such third
party agreement shall control, but only with respect to the use or disclosure, as the
case may be, of Restricted Data.  

4.2     In the
event a party hereto identifies Restricted Data pursuant to Paragraph 4.1 above as
requiring an additional license and the licensee fails to maintain the requisite license
with the applicable third party licensing such data which would permit licensee, at a
minimum, a right to use the Restricted Data provided hereunder in the manner contemplated
herein, then the licensor of such Data hereunder shall have no further requirement to
provide such Restricted Data under the terms of this Agreement until such time as the
receiving party obtains such a license.  

4.3     Each
party hereto shall use its reasonable commercial efforts to avoid third party
restrictions which impair or restrict the rights of the other party to use IMS Data or
Pharbase data, as the case may be, as otherwise permitted by the terms of Paragraph 2.3
and 3.3 respectively. For purposes of the preceding sentence, “reasonable commercial
efforts” shall mean the use of reasonable commercial efforts by a party during the
term of this Agreement to obtain amendments or new agreements with third parties so that
such agreements do not impair or restrict a party’s rights under the terms of this
Agreement in it’s use of Data licensed hereunder other than the applicable
restrictions reflected in Articles II and III.  

     ARTICLE
V —CONFIDENTIALITY 

5.1     ST
     hereby  acknowledges that the IMS Data are proprietary to IMS (collectively
“IMS Confidential Information”),  agree to protect the proprietary and
confidential  nature  of such IMS  Confidential  Information  and in  connection
therewith,  will  prohibit any access to or copying or  disclosure of any of the
IMS  Confidential  Information  during  the  term of this  Agreement  and  after
termination of this  Agreement,  except (a) that access to and disclosure of IMS
Confidential Information may be provided to those employees of ST, in connection
with the uses  permitted ST as described in Article II who require same to carry
out such uses,  and (b) as  expressly  permitted  under  Paragraphs  2.4 of this
Agreement.  ST and any such other persons who receive access to or disclosure of
IMS Confidential  Information  pursuant to the preceding sentence shall maintain
the strict  confidentiality  of such IMS  Confidential  Information  in the same
manner as ST maintains the confidentiality of its own confidential  information,
and ST will not disclose such IMS Confidential  Information  except as expressly
provided herein.  In the event any of such other persons fail to comply with the
confidentiality  obligations  contained in this Paragraph 5.1, ST shall promptly
notify an appropriate  representative of such person in writing of such failure,
with a copy to IMS,  within five  business  days after ST knows or suspects such
failure.  ST shall  promptly  provide IMS with a copy of any responses from such
person to ST’s  notification.  IMS shall have a right to bring an action as
an intended  third party  beneficiary to enforce the terms and conditions of the
agreement   between  ST  and  such  person  with  respect  to   obligations   of
confidentiality.  In the event IMS does not have  rights  as an  intended  third
party  beneficiary to bring an action as  contemplated in this Paragraph 5.1, ST
agrees to cooperate with IMS to pursue such third party for any material  breach
by such person of the terms of such agreement.  ST agrees that it will not ever,
either during the term of this Agreement or after its  termination,  assert that
IMS Data are not,  were not or will not be  proprietary  to IMS and  subject  to
copyright  held by IMS with the  exception of elements of third party data which
are  proprietary to the respective  third party and subject to copyright held by
such third party. 

	

5.2     IMS
     hereby   acknowledges   that  the  Pharbase  Data  are  proprietary  to  ST
(collectively  “ST  Confidential  Information”),  agree to protect the
proprietary and confidential  nature of such ST Confidential  Information and in
connection  therewith,  will  prohibit any access to or copying or disclosure of
any of the ST  Confidential  Information  during the term of this  Agreement and
after termination of this Agreement, except (a) that access to and disclosure of
ST  Confidential  Information  may be  provided  to those  employees  of IMS, in
connection  with the uses  permitted IMS as described in Article III who require
same to carry out such uses, and (b) as expressly permitted under Paragraphs 3.4
of this  Agreement.  IMS and any such other  persons  who  receive  access to or
disclosure of ST  Confidential  Information  pursuant to the preceding  sentence
shall maintain the strict confidentiality of such ST Confidential Information in
the same manner as IMS maintains  the  confidentiality  of its own  confidential
information,  and IMS will not disclose such ST Confidential  Information except
as expressly  provided  herein.  In the event any of such other  persons fail to
comply with the confidentiality obligations contained in this Paragraph 5.2, IMS
shall promptly notify an appropriate representative of such person in writing of
such  failure,  with a copy to ST,  within five business days after IMS knows or
suspects  such  failure.  IMS  shall  promptly  provide  ST  with a copy  of any
responses from such person to IMS’s notification.  ST shall have a right to
bring an action as an intended third party  beneficiary to enforce the terms and
conditions  of the  agreement  between  IMS and  such  person  with  respect  to
obligations  of  confidentiality.  In the  event ST does not have  rights  as an
intended  third party  beneficiary  to bring an action as  contemplated  in this
Paragraph  5.2, IMS agrees to  cooperate  with ST to pursue such third party for
any material  breach by such person of the terms of such  agreement.  IMS agrees
that it will not ever,  either  during the term of this  Agreement  or after its
termination,  assert that IMS Data are not, were not or will not be  proprietary
to ST and  subject to  copyright  held by ST with the  exception  of elements of
third party data which are proprietary to the respective third party and subject
to copyright held by such third party. 

ARTICLE VI —REPRESENTATIONS
     AND WARRANTIES 

6.1     IMS
     represents  and warrants that it has the right and authority to license the
IMS Data to ST under this Agreement. EXCEPT AS EXPRESSLY STATED IN THE PRECEDING
SENTENCE  AND  APPENDIX 1, IMS MAKES NO WARRANTY OR  REPRESENTATION,  EXPRESS OR
IMPLIED,  AS TO THE IMS DATA  (INCLUDING  BUT NOT  LIMITED  TO ANY  WARRANTY  OF
MERCHANTABILITY  OF  SUCH  IMS  DATA OR ITS  FITNESS  FOR  ST’S  PARTICULAR
PURPOSE) AND FURTHER MAKES NO WARRANTY OR REPRESENTATION, EXPRESS OR IMPLIED, AS
TO THE ACCURACY OR COMPLETENESS OF THE IMS DATA. 

	

6.2     ST
     represents  and warrants that it has the right and authority to license the
Pharbase  Data to IMS under this  Agreement.  EXCEPT AS EXPRESSLY  STATED IN THE
PRECEDING  SENTENCE  AND  APPENDIX 1, ST MAKES NO  WARRANTY  OR  REPRESENTATION,
EXPRESS OR IMPLIED,  AS TO THE PHARBASE DATA  (INCLUDING  BUT NOT LIMITED TO ANY
WARRANTY OF  MERCHANTABILITY OF SUCH PHARBASE DATA OR ITS FITNESS FOR IMS’S
PARTICULAR PURPOSE) AND FURTHER MAKES NO WARRANTY OR REPRESENTATION,  EXPRESS OR
IMPLIED, AS TO THE ACCURACY OR COMPLETENESS OF THE PHARBASE DATA. 

ARTICLE VII —LIMITATION
     OF LIABILITY 

7.1     IMS’s
     entire liability and ST’s  exclusive remedy for IMS’s  failure to
abide by the accuracy and  completeness  requirements  of Paragraph 2.2 shall be
for IMS to endeavor to correct,  in accordance  with  IMS’s then applicable
operating procedures for data quality assurance,  any such non-conformance which
has been reported by ST to IMS in writing in a timely manner in accordance  with
the applicable  EXHIBIT.  Notwithstanding  any injunctive relief which ST may be
entitled to, IMS shall not be liable for any indirect, consequential,  punitive,
incidental  or special  damages to person,  property  or  business  which may be
caused by any use,  failure  to  provide  or  unavailability  of IMS Data or any
breach by IMS of its obligations  hereunder (even if IMS has been advised of the
possibility of such damages).  Under no circumstances shall IMS’s liability
hereunder exceed the greater of (a) fifty thousand dollars ($50,000), or (b) the
amount paid by ST to IMS  hereunder in the  immediately  preceding  twelve month
period. 

	

7.2     ST’s
     entire liability and IMS’s  exclusive remedy for ST’s  failure to
abide by the accuracy and  completeness  requirements  of Paragraph 3.2 shall be
for ST to endeavor to correct,  in accordance  with  ST’s  then  applicable
operating procedures for data quality assurance,  any such non-conformance which
has been reported by IMS to ST in writing in a timely manner in accordance  with
the applicable  EXHIBIT.  Notwithstanding any injunctive relief which IMS may be
entitled to, ST shall not be liable for any indirect,  consequential,  punitive,
incidental  or special  damages to person,  property  or  business  which may be
caused by any use, failure to provide or  unavailability of Pharbase Data or any
breach by ST of its  obligations  hereunder  (even if ST has been advised of the
possibility of such damages).  Under no circumstances  shall ST’s liability
hereunder exceed the greater of (a) fifty thousand dollars ($50,000), or (b) the
amount paid by IMS to ST hereunder  in the  immediately  preceding  twelve month
period. 

     ARTICLE
VIII —TERM/TERMINATION 

The term of this Agreement shall be
for a three year period commencing on the date first written above. Notwithstanding the
foregoing, either party shall have the right to terminate this Agreement on thirty (30)
days advance written notice to the other party:  

8.1     if such
     other  party  becomes  insolvent,  voluntarily  files a petition  under any
federal or state  bankruptcy law for itself,  has an involuntary  petition filed
under any federal,  provincial or state  bankruptcy  law against it which is not
removed within thirty (30) days of filing, ceases operations for at least thirty
(30) days with the intent of winding up such party’s business, or otherwise
publicly announces the termination of its operations; or 

8.2     upon the
     sale of such other party, whether by merger, consolidation, the sale of its
stock or by the sale of all or  substantially  all of its assets to a  Competing
Company  or any  person or Entity  controlling,  controlled  by or under  common
control with a Competing Company. 

ARTICLE IX —FORCE
MAJEURE  

Neither party shall be deemed to
     have  breached  this  Agreement  or to be liable for any damages  caused by
failure to perform or by delay in rendering performance hereunder arising out of
any occurrence or contingency beyond its reasonable  control,  including but not
limited to, (a) flood, earthquake, fire, war, strikes, labor unrest, riot, civil
commotion,  power or communication  line failure,  computer equipment failure or
operational failure, (b) failure of independent contractors under agreement with
IMS to perform or a delay in such performance,  failures, delays or restrictions
of sources from which information or data is obtained, or failure of performance
by Licensee,  or (c)  prohibition(s)  or  restriction(s)  imposed by  applicable
regulatory  authority,  the  judgment,  ruling  or order of a court or agency of
competent jurisdiction,  or the enactment of or change in any law or regulation.

	

ARTICLE X —ADDITIONAL
AGREEMENTS  

10.1     IMS and
     ST each agree to keep the terms of this  Agreement  in  confidence  and not
disclose  them to any other  Person,  except  for those  terms of the  Agreement
required to be  disclosed  (i)  pursuant to federal,  state or national  laws or
regulations including securities laws and their related disclosure requirements,
(ii) pursuant to judicial or arbitration orders and proceedings, (iii) as may be
required to perform their obligations  under this Agreement,  or (iv) to each of
IMS’s and Licensee’s  legal and financial  representatives who need to
know such terms solely for the purpose of providing  legal and financial  advice
to each such party, respectively. This provision shall not prohibit either party
from  disclosing  the existence of this  Agreement or that IMS is a data source.

10.2     Under
     no  circumstances   shall  this  Agreement  be  construed  as  placing  any
affirmative  obligation  on either  party,  express  or  implied,  to collect or
continue to collect any data or information  from any third party from which the
IMS Data or Pharbase Data is derived (“Source  Data”).  In the event a
party  hereto  determines,  in  its  sole  judgment  and  discretion,  to  cease
collecting  any Source Data which will result in a substantial  reduction in the
amount  of, or  cessation  in,  the Data  delivered  hereunder,  such party will
provide  written  notice of such to the other party  hereto at least ninety (90)
days  prior  to the  date on which  such  Source  Data  collection  will  cease,
specifying the date or dates at which it will cease  collecting such Source Data
and the amount of Data that will be deleted as a result (the  Notice”).  In
such event,  the party hereto giving such Notice shall incur no liability to the
other party in connection therewith and, in the event the notifying party ceases
to collect all of such Source  Data,  then this  Agreement  shall  automatically
terminate and be of no further force and effect upon the effective  date of such
cessation. 

ARTICLE XI —ARBITRATION  

11.1     Each
     party shall  designate a project  manager to coordinate  such  party’s
activities  under  this  Agreement.  Such  project  managers  shall  also,  when
necessary,  confer in order to resolve  problems or  disputes  that may arise in
connection with each party’s performance hereunder. If the project managers
cannot  resolve such problems or disputes,  such  problems or disputes  shall be
referred to each  party’s  respective  senior management for discussion and
resolution. 

11.2     Subject
     to Paragraph  11.4, any  controversy or claim arising out of or relating to
this  Agreement,  and which cannot be resolved in accordance  with the procedure
set forth in the preceding paragraph, shall be submitted to arbitration before a
panel of three  (3)  arbitrators.  The  arbitrators  shall be  selected  and the
arbitration conducted in accordance with the _________________________. An award
shall be conclusive  and binding if concurred in by two (2) of the  arbitrators,
and judgment upon the award  rendered by the  arbitrators  may be entered in any
court having jurisdiction  thereof. The arbitrators shall be required to deliver
a written  decision  setting  forth  their  findings of fact and basis for their
award.  The  arbitrators’  award  shall  provide  for  the  payment  of the
arbitrators’  expenses and fees,  together with other expenses  incurred in
the conduct of the  arbitration  proceeding  other than legal fees and expenses.
However,   the  arbitrators   shall  award  the  prevailing   party   reasonable
attorneys’  fees and other expenses incurred in the arbitration  proceeding
in the event that the arbitrators determine that either party acted in bad faith
in  connection  with either  asserting  a claim or a defense in the  arbitration
proceeding itself. 

	

11.3     The
     parties hereby agree to submit to the exclusive  personal  jurisdiction and
venue of the  _______________________________  for  purposes  of  enforcing  the
agreement to arbitrate,  providing  provisional  relief  pending the award,  and
entering  judgment on the award.  If for any reason the aforesaid court does not
have subject matter jurisdiction,  the parties  alternatively agree to submit to
the exclusive  personal  jurisdiction  and venue of the applicable  court of the
_____________________  for the  foregoing  purposes.  Nothing  contained in this
paragraph  shall  preclude the  arbitrators  from granting,  where  appropriate,
injunctive or other provisional relief pending a final award. 

11.4     Notwithstanding
     the provisions of Paragraphs 11.2 and 11.3, any party hereto may pursue any
provisional remedy (including but not limited to preliminary  injunctive relief)
to enforce its rights hereunder in the courts  designated in Paragraph 11.3. The
parties shall have the right to obtain such provisional injunctive relief from a
court of law designated in Paragraph 11.3 pending the determination and award in
the  arbitration  proceeding.  The parties  may seek  injunctive  relief  either
restraining  certain conduct or mandating  certain conduct.  This Paragraph 11.4
shall not be deemed to limit the power of the arbitrators to grant any remedy or
relief  the  arbitrators  deem  just or  reasonable  within  the  scope  of this
Agreement. 

11.5     The
     parties agree that,  immediately  upon the designation of the  arbitrators,
they will request the  arbitrators  that they set an expedited  schedule for the
conduct of the  arbitration  proceeding  such that the  proceeding  is concluded
within six months of the date of the filing of a demand for arbitration and that
an award shall be rendered  within  thirty  (30) days of the  conclusion  of the
proceeding. 

ARTICLE XII —DATA
PROTECTION OBLIGATIONS  

The parties agree to procure that
those of their respective Affiliates listed in Exhibits 1 and 2 hereto and which are
established within the European Union abide by the additional obligations set out in
Appendix 1 as if they were incorporated as terms and conditions of this Agreement.  

	

     ARTICLE
XIII —MISCELLANEOUS 

13.1     The
     parties  hereto are  independent  contractors  engaged in the  operation of
their own  respective  businesses.  Neither party is, or is to be considered as,
the agent or employee of the other for any purpose whatsoever. Neither party has
the authority to enter into  contracts or assume any  obligations  for the other
party or make any  warranties or  representations  on behalf of the other party.
Nothing in this  Agreement  shall be construed to  establish a  relationship  of
co-partners or joint venturers between the parties. 

13.2     This
     Agreement  (including the exhibits and Appendix 1)  constitutes  the entire
understanding  between the parties and supersedes  all  proposals,  commitments,
writings,  negotiations  and  understandings,  oral and  written,  and all other
communications  between  the  parties  relating  to the  subject  matter of this
Agreement. 

13.3     Either
     party may assign all or any portion of this Agreement to an entity which is
then an Affiliate  and any such  Affiliate may assign all or any portion of this
Agreement to an entity which is then a Affiliate;  provided,  however,  that any
such assignment  shall not relieve the assigning party of its obligations  under
this  Agreement.  This Agreement may not be assigned from ST to any other person
or Entity, whether by assignment by ST, by operation of law or otherwise without
the prior  written  consent  of IMS  which  consent  shall  not be  unreasonably
withheld.  The sale or  transfer  of a  majority  of the  outstanding  shares of
Licensee,  or the merger or consolidation of ST with any other person or Entity,
shall be deemed an attempt by ST to assign its interests in this Agreement which
shall  first  require  the prior  written  consent of IMS.  Any  assignment  not
expressly  permitted  under this  Paragraph  13.3 or which has not  received the
written consent of the other party if required herein shall be void. 

13.4     Should
     any part, term or condition  hereof be declared illegal or unenforceable or
in  conflict  with any other  law,  the  validity  of the  remaining  portion or
provisions of this Agreement shall not be affected  thereby,  and the illegal or
offensive  portions  of this  Agreement  shall be and  hereby are  redrafted  to
conform with  applicable  law in a manner which is consistent  with the original
spirit and intent  embodied in the  original  executed  copy of this  Agreement,
while leaving the remaining portions of this Agreement intact. 

13.5     The
     waiver by either party of a breach or violation  hereof or remedy  provided
herein  shall not operate as or be  construed  to be a waiver of any  subsequent
breach or violation hereof. 

13.6     This
     Agreement  (save for  Appendix  1) shall be governed  by and  construed  in
accordance with the laws of the __________________________ without giving effect
to principles of conflicts of law. 

13.7     Nothing
     in this Agreement is intended to benefit and shall not be deemed to benefit
any person who is not a party  hereto or to create any third  party  beneficiary
rights. 

	

13.8     All
     notices  pertaining to this  Agreement or the  performance  of either party
hereunder  shall be  sufficient  if in writing and sent by DHL or other  similar
overnight courier service with receipted  delivery  addressed to the other party
at the address  shown  below or to such other  address as a party  hereto  shall
supply to the other in writing: 

			
		If to IMS:

	
			
			IMS Health
			7 Harewood Avenue
			London, NW1 6JB
			England
			Attention:  President, European Region

			
		With a copy to:

	
			
			IMS HEALTH
			7 Harewood Avenue
			London, NW1 6JB
			England
			Attention:  Law Department

			
		If to Licensee:

	
			
			Synavant Inc.
			3445 Peachtree Road, N.E.
			Suite 1400
			Atlanta, GA 30026
			Attention:  President

	 	
Such notice shall be effective upon receipt by the other party 

	

13.9         Neither
     party  may  under  any  circumstances  utilize  the  name,  trademarks,  or
tradenames of the other, or any names,  trademarks,  or tradenames so similar as
likely to cause  confusion,  without  the prior  written  notice to, and express
written approval of, the other.  Notwithstanding  the preceding  sentence,  each
party  shall have a right to  identify  to any  person or Entity  that the other
party is a supplier and licensee of Data hereunder. 

13.10     Paragraph
     headings herein are for  convenience  only and do not control or affect the
meaning  or  interpretation  of any  terms  or  provisions  of  this  Agreement.

	

ARTICLE XIV — FEES  

The annual fee payable by IMS for
     the services  described in this  Agreement  for each Contract Year shall be
one million five hundred  thousand  dollars  ($1,500,000).  ST shall invoice one
quarter of the  annual  fee on a  quarterly  basis in  advance  (i.e.,  ST shall
invoice  three  hundred  seventy-five  thousand  dollars  ($375,000) on or about
September 1st, December 1st, March 1st, and June 1st of each Contract Year). IMS
shall  pay the  amount of each  invoice  from ST  within  thirty  (30) days from
receipt of invoice by IMS. In no event shall IMS deduct or set-off any amount(s)
against any amount(s) owed to ST under this Agreement  without  ST’s  prior
written  consent.  If IMS fails to timely pay any amount in accordance  with the
terms of this  Agreement,  IMS  shall pay in  addition  to the  invoice  amount,
interest at the rate of eighteen  percent (18%) per annum on the unpaid  balance
beginning  thirty-five (35) days from the date of the invoice until such amounts
are paid.  In addition  to any fees which IMS agrees to pay,  IMS shall have the
exclusive  responsibility  for and  agrees  to pay all  applicable  governmental
sales, use, added value, ad valorem or other similar taxes, duties, fees, levies
or other governmental charges now in force or enacted in the future,  except for
taxes based on ST’s income. 

IN WITNESS WHEREOF, the parties have
executed this Agreement on the date first written above.  

			
	IMS Health Incorporated:

	 	Synavant Inc.:

	By: /s/ Matthew L. Friedman
	 	By: /s/ James C. Malone       
	Name: Matthew L. Friedman
	 	Name: James C. Malone
	Title: Vice President	 	Title: Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]